Tumor necrosis factor alpha (TNF␣) contributes to the pathogenesis of many chronic inflammatory diseases, including rheumatoid arthritis, diabetes, hepatitis, and some causes of pulmonary inflammation and fibrosis (14, 16, 27, 29, 49, 53, 54) . The controlled expression of TNF␣ is critical during sepsis and adipocyte differentiation and in obesity (9, 19, 20, 22, 49) . Although macrophages are the principal source of TNF␣ secretion in conditions such as rheumatoid arthritis and sepsis (27, 49) , the cytokine is produced by a wide variety of cells, including lymphocytes, adipocytes, mast cells, keratinocytes, and astrocytes.
A number of transcription factors contribute to the complex regulation of the TNF␣ gene, and interactions between factors may vary depending on the cell type and the particular extracellular stimuli. The transcription factor C/EBP␤ (also called NF-IL6, NF-M, LAP, IL6-DBP, AGP/EBP, and CRP2) (1) has been shown to be important in TNF␣ gene activation in myelomonocytic cells (38) . It binds to the TNF␣ promoter at a site between 74 and 100 bp upstream of the transcription start site (38) and may also be important for the expression of TNF␣ in other cell types, such as hepatocytes and adipocytes, which also express C/EBP␤.
Several types of evidence suggest that C/EBP␤ works in concert with other transcription factors to regulate the TNF␣ promoter in a cell-type-specific fashion. For example, the TNF␣ promoter contains potential binding sites for several additional transcription factors, including AP-1, AP-2, NF-B, NFAT, Ets, SP-1, and cyclic AMP response element (CRE) (see Fig. 1 ) (13, 15, 25, 33, 38, 39, 48) . The transcription factors AP-1, Ets, and NFAT have been shown to play important roles in the activation of the TNF␣ gene (13, 15, 23, 33, 39, 48) . In addition, C/EBP␤ synergizes with a variety of transcription factors, including c-Jun, NF-B, Myb, and the glucocorticoid receptor, to regulate other genes (7, 17, 21, 23, 26, 32, 35, 42, 43) . However, very little is known about interactions between C/EBP␤ and other transcription factors in the cell-type-specific regulation of the TNF␣ gene.
Here we describe interactions between C/EBP␤ and the transcription factor AP-1 which affect the regulation of the TNF␣ gene. We showed that c-Jun binds adjacent to C/EBP␤ on the TNF␣ promoter and synergistically activates the C/EBP␤-dependent expression of the TNF␣ gene in phorbol myristate acetate (PMA)-treated Jurkat T cells. This cooper-ation required the DNA binding domain of c-Jun and an intact AP-1 binding site on the TNF␣ promoter, suggesting that both C/EBP␤ and c-Jun must bind in order to coactivate the gene. U937 cells stably overexpressing wild-type c-Jun secreted increased TNF␣. Interestingly, C/EBP␤ also cooperated with the mutant form of c-Jun lacking the transcriptional transactivation domain, in both Jurkat T cells and U937 cells, suggesting that the cooperation between c-Jun and C/EBP␤ is not just the additive effect of independent transcriptional activation domains.
MATERIALS AND METHODS
Plasmid vector constructs. The TNF␣ promoter reporter constructs containing 615, 120, or 95 bp 5Ј of the transcription start site, linked to a luciferase gene, have been described elsewhere (13, 38) , as have the expression vectors (cytomegalovirus encoding wild-type [CMV]-C/EBP␤) and dominant negative (CMV-5D229) versions of C/EBP␤ (38) . c-jun and c-jun mutant human cDNAs were cloned into the CMV vector plasmid and have been previously characterized (2, 6, 18, 36) . Mutations had been generated by deletion of the leucine zipper (c-Jun-LZ), the DNA binding (c-Jun-DBD), and the transactivation (transactivation domain mutant TAM-67) domains (2, 6, 18, 36) . Human c-fos was cloned into a pSV vector (2, 6) . The pCDM8 (Invitrogen, San Diego, Calif.), pSV, and CMV vectors were used as controls. A promoter-reporter construct containing dual c-Jun binding sites from the interleukin-2 (IL-2) promoter [TRE(IL-2)-Luc] was used as a control (36) . The p300-and CREB-binding protein (CBP)-expressing plasmids have been previously described (10, 12) . Luciferase-expressing plasmids possessing the AP-1 and C/EBP␤ binding sites of the TNF␣ gene were constructed by using pT81-Luc, which possessed a weak tk promoter. Two plasmids, constructed by using oligonucleotides representing Ϫ115 to Ϫ74 bp of the TNF␣ promoter, possess 0 (pT81TNF0bp) or 10 (pT81TNF10bp) irrelevant bp inserted between Ϫ98 and Ϫ97 bp. Since the two sites overlapped, Ϫ99 and Ϫ100 were included on both sides of the inserted base pairs. Plasmids were screened by restriction digestion, and the sequences were confirmed by DNA sequencing employing the dideoxynucleotide method.
Transfection and luciferase assay. Jurkat T cells were maintained in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum, L-glutamine, and penicillin-streptomycin (complete medium). Transfection of Jurkat T cells was performed by the DEAE-dextran method as previously described (38) , keeping the total plasmid concentration constant (8 g). Transfection of U937 cells was performed by electroporation (38) , keeping the total DNA concentration at 16 g/transfection. After transfection, cells were placed in complete medium for 4 to 6 h, and then PMA (10 ng/ml), alone or with lipopolysaccharide (LPS; 1 g/ml), or ionomycin (0.5 M) or control buffer, as indicated in the individual experiments, was added for an additional 12 h. Cells were harvested, washed, and lysed by freeze-thawing three times, and luciferase activities were determined on cell lysates as previously described (38) , using a Monolight 2010 luminometer (Analytical Luminescence Laboratory, San Diego, Calif.). Promoter activities were expressed as relative light units (RLU), normalized for the total protein in each extract.
Oligonucleotides and electrophoretic mobility shift assay. Synthetic oligonucleotide probes were prepared which spanned the following regions of the TNF␣ promoter: Ϫ100 to Ϫ74 (Ϫ100/Ϫ74) (29) , Ϫ115 to Ϫ74 (Ϫ115/Ϫ74), and Ϫ115 to Ϫ98 (Ϫ115/Ϫ98) (Fig. 1) . Oligonucleotides representing the C/EBP␤ binding site of the IL-6 promoter and an AP-1 binding site from the collagenase promoter have been previously described (1, 3) . Recombinant C/EBP␤ was expressed in insect cells, using a baculovirus vector, as previously described (38) . Recombinant c-Jun was obtained commercially (Promega Corp., Madison, Wis.), as were antibodies specific for C/EBP␤ and c-Jun (Santa Cruz Inc., Santa Cruz, Calif.). Electrophoretic mobility shift assays were performed as described previously (38), using 1 ng of 32 P-labeled probe per reaction. DNA-binding complexes were analyzed by electrophoresis on a 4% nondenaturing polyacrylamide gel in buffer containing 67 mM Tris-HCl (pH 8.0), 10 mM EDTA, and 33 mM sodium acetate. Gels were dried and exposed to radiographic film overnight at Ϫ80°C.
Cell lines. Jurkat and U937 cell lines were obtained from the American Type Culture Collection (Rockville, Md.) and maintained in complete medium as described above (38) . U937 cell lines stably transfected with plasmids expressing a neomycin resistance gene alone or together with plasmids expressing the wild-type c-Jun or TAM-67 have been previously described and characterized (18, 45) . These cell lines were maintained in medium containing 400 g of G418 per ml.
TNF␣ secretion and quantitation. U937 cell lines expressing the neomycin resistance gene alone or together with wild-type c-Jun or TAM-67 were plated at 0.5 ϫ 10 6 /ml in complete medium. PMA (10 ng/ml), or PMA plus LPS (1 g/ml), or control medium was added, and cells were incubated for 18 h. Supernatants were harvested and frozen at Ϫ20°C. TNF␣ was measured by enzyme-linked immunosorbent assay using commercially available reagents as described previously (8) .
RESULTS
C/EBP␤ and c-Jun proteins synergistically activate the TNF␣ gene. Our prior data (38) showed that C/EBP␤ was important in activating a promoter reporter gene construct possessing as little as 120 bp of the TNF␣ promoter (Ϫ120 TNF␣-luciferase). However, this promoter reporter also possesses two functional AP-1 binding sites centered at 102/103 and 62 bp upstream from the transcription start site (Fig. 1) . We used cotransfection assays in Jurkat T cells, which do not express endogenous C/EBP␤, under conditions in which c-Jun was not significantly activated (38, 44) , in order to determine if there was an interaction between C/EBP␤ and AP-1 complex transcription factors in regulation of the TNF␣ promoter.
First, the ability of individual proteins to activate the Ϫ120 TNF␣ promoter reporter construct was assessed. Consistent with our earlier observations (38) , cotransfection of 2 g of the C/EBP␤ expression vector with the Ϫ120 TNF␣ promoter reporter construct resulted in a 46 Ϯ 7 (standard error [SE])-fold enhancement of PMA-induced activation in Jurkat T cells ( Fig.  2A) . Increasing the concentration of CMV-C/EBP␤ up to 4 g/transfection resulted in greater activation (Ͼ70-fold [data not shown]). Ectopic expression of wild-type c-Jun resulted in up to 14 Ϯ 3 (SE)-fold stimulation of TNF␣ promoter reporter activity ( Fig. 2A) . Wild-type c-Jun was also able to activate the TNF␣ promoter reporter to a limited extent in cells that were not treated with PMA (data not shown), consistent with earlier reports (25) . However, no other expression vector, including CMV-C/EBP␤, resulted in any activation of the TNF␣ promoter, either alone or in combination, in the absence of PMA treatment. This finding suggests that in Jurkat T cells, PMA enhanced the activity of c-Jun but was essential for the transcriptional activation mediated by C/EBP␤.
Next, we examined cooperation between C/EBP␤ and c-Jun by cotransfecting plasmids expressing both proteins (Fig. 2B) . The data for each experiment, prior to statistical analysis, were normalized to the activation induced by the CMV-C/EBP␤, which was defined as 100%. As shown in Fig. 2B , there was no change in TNF␣ promoter activity when additional CMV vector was cotransfected with the plasmid expressing C/EBP␤. However, cotransfection of C/EBP␤ plus low concentrations of FIG. 1. Sequence of the human TNF␣ promoter region Ϫ123 bp upstream from the transcription start site (TSS). Previously described binding sites for C/EBP␤ (Ϫ100 to Ϫ74 bp), AP-1 (Ϫ106 to Ϫ99 and Ϫ65 to Ϫ59 bp), AP-2 (Ϫ36 to Ϫ28 bp), SP-1 (Ϫ52 to Ϫ45 bp), Ets (Ϫ116 to Ϫ112 bp), NFAT and NF-B (Ϫ97 to Ϫ88 bp), and CRE (Ϫ106 to Ϫ99) are indicated on the sequence representing the first 123 bp of the TNF␣ promoter (13, 15, 25, 33, 38, 39, 48) . The C/EBP␤ binding site was defined by using the 32 P-oligonucleotide employed in this study (38) . The sites highlighted by the bold boxes are the focus of this study.
the c-Jun-expressing plasmid (0.25 or 0.5 g) resulted in a significant (P Ͻ 0.05) 3-fold synergistic activation of the TNF␣ promoter (Fig. 2B) , representing Ͼ130-fold activation above the PMA-treated baseline. Higher concentrations of the plasmid expressing c-Jun (2.0 and 3.0 mg) resulted in significant (P Ͻ 0.02) inhibition of C/EBP␤-induced TNF␣ promoter activity. No such suppression was observed with comparable concentrations of CMV-C/EBP␤ vector (data not shown) or the control CMV vector (Fig. 2B) , excluding squelching by the CMV promoter as the cause of this suppression and suggesting that the inhibition was the effect of c-Jun overexpression.
To determine if the effects of c-Jun were specific, another component of the AP-1 complex, c-Fos, was also examined. tion mutants of c-Jun alone resulted in little or no activation of the TNF␣ promoter reporter in PMA-treated Jurkat T cells ( Fig. 2A ). In addition, no synergy was observed when c-Jun-LZ was coexpressed with C/EBP␤ (Fig. 2B ). These observations suggest that protein-protein interactions, most likely involving the c-Jun leucine zipper, were necessary for the synergistic activation of the TNF␣ gene by C/EBP␤ and c-Jun. To determine if c-Jun DNA binding was required, the c-Jun-DBD mutant, which is capable of dimerization but not DNA binding, was also used. No synergy with C/EBP␤ was observed (Fig.  2B) , suggesting that binding of c-Jun homodimers or formation of a complex of c-Jun and C/EBP␤ was necessary for the observed synergistic activation. Unexpectedly, the ectopic expression of TAM-67, which has the c-Jun DNA binding and dimerization domains intact but lacks the transactivation domain, enhanced the activation of the TNF␣ promoter by C/EBP␤ (P Ͻ 0.02 at 0.25 and 0.5 g) (Fig. 2B) . The TAM-67 results suggest that the observed synergism of c-Jun with C/EBP␤ was not due to additive effects of heterologous transactivation domains but more likely involved direct proteinprotein interactions or cooperative DNA binding to the TNF␣ promoter.
The ability of the TAM-67 transactivation domain deletion mutant of c-Jun to activate gene expression on its own and to inhibit wild-type c-Jun was examined. TAM-67 had no effect on the TNF␣ promoter reporter ( Fig. 2A ), indicating that it was not sufficient to activate this promoter on its own. To determine if TAM-67 inhibited c-Jun activity in our system, TAM-67-and c-Jun-expressing plasmids were cotransfected along with TRE(IL-2)-Luc, a c-Jun-responsive reporter plasmid derived from the IL-2 gene promoter. When transfected alone, no activation of the TRE(IL-2)-Luc promoter reporter was noted in PMA-activated Jurkat cells (data not shown), consistent with lack of substantial activation of endogenous c-Jun under these conditions (44) . However, cotransfection of TAM-67, but not the empty CMV vector, effectively inhibited the activation of this promoter by ectopically expressed c-Jun (Fig. 2C ). These observations confirm that the TAM-67 deletion mutant can act in a dominant-negative fashion and that alone, it is incapable of activating TNF␣ gene expression. However, TAM-67 was able to synergize with C/EBP␤ to activate the TNF␣ promoter (Fig. 2B) , suggesting that it did so via protein-protein interactions which were independent of the c-Jun transactivation domain.
c-Jun must bind the TNF␣ promoter to synergize with C/EBP␤. Prior studies have indicated that AP-1 binding sites centered 62 and 102/103 bp upstream of the transcription start site were involved in TNF␣ gene activation (25, 39) . The contribution of these sites for the enhancement of C/EBP␤-induced activation by c-Jun was examined. Since synergistic interactions between c-Jun and C/EBP␤ were evident in assays using the Ϫ615 AP-1 mutant TNF␣ promoter reporter, which possesses a 2-base substitution at Ϫ65 and Ϫ66 bp of the TNF␣ promoter (data not presented), we reasoned that the AP-1 binding site at that position was not required for synergism with C/EBP␤. Therefore, we compared the Ϫ95 TNF␣-luciferase promoter reporter construct, which possesses the C/EBP␤ binding site (38, 50) but lacks the AP-1 site centered at Ϫ103/Ϫ102 bp (25, 33) , to the Ϫ120 TNF␣ promoter reporter, in which the AP-1 site is present. The initial cotransfection assays were performed at a limiting concentration of CMV-C/EBP␤ (1 g), which we had determined in preliminary studies more sensitively detected the potential synergistic effects of added c-Jun. The two promoter reporter constructs were comparably activated by cotransfection of 1 g of C/EBP␤ expression vector in PMA-treated Jurkat T cells (Fig.   3A) . However, unlike the results observed with the Ϫ120 construct, no synergy between C/EBP␤ and c-Jun was observed when the Ϫ95 TNF␣ promoter was used. Additional experiments were performed with the Ϫ95 promoter reporter construct, using 2 g of CMV-C/EBP␤ and each of the c-Jun constructs (Fig. 3B) . Again in contrast to the results observed with the Ϫ120 TNF␣ promoter (Fig. 2B) , cotransfection of TAM-67 with the Ϫ95 TNF␣ promoter reporter had no effect on C/EBP␤-induced activation (Fig. 3B) . Since the Ϫ95 TNF␣ promoter reporter plasmid still possessed the AP-1 binding site centered 62 bp upstream of the transcription start site, the data confirm that this AP-1 site was not responsible for the synergistic enhancement of C/EBP␤-induced activation of the TNF␣ promoter by c-Jun in PMA-treated Jurkat T cells. Thus, synergism between c-Jun and C/EBP␤ required a c-Jun binding site in the promoter as well as expression of c-Jun proteins containing both the DNA binding and dimerization domains, strongly suggesting that DNA binding by c-Jun was essential.
The transactivation domain of c-Jun mediates suppression of C/EBP␤-induced activation in Jurkat T cells. Cotransfection of either wild-type c-Jun or the c-Jun-LZ mutant resulted in significant (P Ͻ 0.05 to 0.005 at 0.5 to 3 g) suppression of the C/EBP␤-induced activation of both the Ϫ120 and the Ϫ95 TNF␣ promoter reporters ( Fig. 2B and 3B ), suggesting that dimerization or protein-protein interactions mediated by the leucine zipper were not necessary for suppression. In contrast to the results with wild-type c-Jun, suppression was not observed at any concentration of TAM-67 with either the Ϫ120 or Ϫ95 TNF␣ promoter reporter construct ( Fig. 2B and 3B ). These observations suggest that the c-Jun transactivation domain contributed to the inhibition of C/EBP␤-induced activation of the TNF␣ promoter and that this repression was independent of the AP-1 binding site. The explanation for the lack of suppression observed with the c-Jun DNA binding mutant ( Fig. 2B and 3B ) remains unclear. The suppressive effect was not specific for c-Jun since c-Fos, at similar concentrations, also suppressed C/EBP␤-induced activation (data not shown).
Potential contribution of other transcription factors or coactivators to C/EBP␤-c-Jun-mediated TNF␣ activation. Earlier studies demonstrated that NFAT was important in the activation of the TNF␣ gene in T cells under certain conditions (15, 48) . Jurkat T cells possess NFAT, which requires two signals, such as PMA plus ionomycin, for optimal activation. Since activation of the TNF␣ gene by NFAT was inhibited by cyclosporin A (48), this inhibitor was used to determine if the TNF␣ promoter expression induced in response to C/EBP␤ plus PMA in Jurkat T cells was mediated by the activation of NFAT. Following transfection with CMV-C/EBP␤ and stimulation with PMA, no inhibition of TNF␣ promoter activation was observed by adding cyclosporin A (data not shown). In contrast, activation of the TNF␣ promoter induced by PMA plus ionomycin, in the absence of C/EBP␤, was inhibited Ͼ90% by cyclosporin A, suggesting that cyclosporin A inhibited NFAT-induced TNF␣ promoter activation, as previously described (15, 48) .
CBP and p300 have been identified as nuclear phosphoproteins capable of interacting with a variety of transcription factors, including c-Jun and C/EBP␤ (4, 5, 28a) . Vectors expressing either p300 or CBP were cotransfected into Jurkat T cells together with c-Jun, C/EBP␤, and the Ϫ120 TNF␣ promoter reporter. No enhancement of activation of the TNF␣ promoter by either CBP or p300 was observed in Jurkat T cells either unstimulated or treated with PMA (data not shown). Additionally, neither CBP nor p300 expression reversed the c-Juninduced suppression of TNF␣ promoter reporter activation by C/EBP␤ (data not shown). These data suggest that neither NFAT, CBP, nor p300 contributed to the enhanced activation of the TNF␣ promoter by C/EBP␤ plus c-Jun.
Overexpression of c-Jun and TAM-67 was associated with increased TNF␣ secretion in U937 cell lines. The results described above implicate c-Jun in the regulation of the TNF␣ promoter but do not address whether similar mechanisms also regulate the chromosomal TNF␣ gene. Since monocytes/macrophages are the principal source of TNF␣, we used the myelomonocytic cell line U937 to test whether ectopic expression of wild-type c-Jun or TAM-67 would affect the synthesis and secretion of TNF␣. U937 cells constitutively express C/EBP␤, and the concentration was increased by differentiation in response to PMA (31) . Therefore, we examined TNF␣ secretion in three independently derived stably transfected U937 cell lines overexpressing c-Jun and one line expressing TAM-67, each of which have been previously characterized (18, 45) , as well as a similar line transfected only with the neomycin resistance gene. Western blots confirmed the increased wild-type c-Jun, both constitutively and following PMA-LPS treatment, in the c-jun-transfected lines compared to the control (data not shown). The TAM-67-transfected line expressed abundant TAM-67, and the wild-type c-Jun level was comparable to that in the neomycin-transfected control cell line (data not shown). Interestingly, no TNF␣ was secreted by these lines constitutively or when the cells were differentiated with PMA alone (data not shown). However, following differentiation plus activation by LPS, TNF␣ was secreted by each of the lines. TNF␣ secretion was significantly increased (P Ͻ 0.02) in the lines overexpressing either wild-type c-Jun or TAM-67 compared to the control (Fig. 4) , suggesting that wild-type and TAM-67 c-Jun proteins can enhance TNF␣ protein production by myelomonocytic cells.
TAM-67-C/EBP␤ interaction in U937 cells was associated with enhanced activation of the TNF␣ promoter reporter. To determine if the AP-1 site centered 102/103 bp 5Ј of the transcription start site was involved in the enhanced activation observed in the U937 line expressing TAM-67, this line and the control U937 line were transfected with either the Ϫ120 or the Ϫ95 TNF␣-luciferase promoter reporters. The TAM-67 line, rather than a c-Jun-overexpressing line, was used to avoid potential activation by the wild-type c-Jun through the AP-1 site centered at Ϫ62 bp of the promoter. The Ϫ95 TNF␣ construct does not possess the AP-1 site centered at Ϫ102/ Ϫ103 bp (Fig. 1) but does retain the ability to become activated by C/EBP␤ (Fig. 3B) . In the control neomycin-transfected U937 line, the Ϫ120 TNF␣ promoter-reporter demonstrated no increased activation compared to the Ϫ95 TNF␣ promoter reporter (Fig. 5A) . In contrast, the Ϫ120 TNF␣ construct demonstrated a fourfold activation compared to the Ϫ95 TNF␣ construct in the U937 line stably expressing TAM-67 (Fig. 5A) . This observation suggests that the enhanced activation of the TNF␣ promoter in U937 cells overexpressing TAM-67 was mediated through the AP-1 site centered at Ϫ102/Ϫ103 bp. This observation further documents that the Ϫ62 bp AP-1 site was not involved in the enhanced activation of the Ϫ120 TNF␣ promoter reporter observed in the TAM-67 cells, similar to the results observed in the Jurkat T cells.
The U937 cell line stably transfected with TAM-67 was next used to determine if C/EBP␤ was cooperating with TAM-67 to activate the TNF␣ promoter. A dominant negative version of 
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on February 21, 2013 by PENN STATE UNIV http://mcb.asm.org/ C/EBP␤, with the transactivation domain deleted, was cotransfected together with the Ϫ120 TNF␣ promoter-reporter. Cotransfection of this construct, DN C/EBP␤, resulted in significant (P Ͻ 0.05) suppression of TNF␣ activation in the U937 cell line expressing TAM-67, while the control vector had no significant effect (Fig. 5B) . The suppression may be even more impressive than is apparent since TAM-67 and wild-type C/EBP␤ were constitutively present at the time of the transfection, while DN C/EBP␤ required additional time for expression. When the TAM-67-transfected U937 cells were treated with PMA plus LPS, conditions required for TNF␣ secretion, cotransfection of DN C/EBP␤ with the TNF␣ promoter-reporter also resulted in significant (P Ͻ 0.05) suppression (data not shown). Together, these observations suggest that C/EBP␤ interacted with TAM-67 to effect the enhanced activation of the Ϫ120 TNF␣ promoter observed in these cells. c-Jun affects the DNA binding of C/EBP␤ to the TNF␣ promoter. The transfection assays described above suggested that c-Jun must bind the TNF␣ promoter to enhance C/EBP␤ activity. To further characterize the interactions between c-Jun and C/EBP␤, in vitro DNA binding assays were performed with three different 32 P-labeled oligonucleotides derived from the TNF␣ promoter. The Ϫ115/Ϫ98 oligonucleotide contained only the crucial c-Jun binding site described above. The Ϫ100/ Ϫ74 oligonucleotide contained the C/EBP␤ binding site but no AP-1 site, and the Ϫ115/Ϫ74 oligonucleotide spanned both sites. C/EBP␤ bound readily to the 32 P-labeled Ϫ100/Ϫ74 bp oligonucleotide (Fig. 6A, lane 1) . This binding has been shown to be specific since it was efficiently competed by adding an excess of either unlabeled Ϫ100/Ϫ74 oligonucleotide or another C/EBP␤-binding oligonucleotide derived from the IL-6 promoter, and it was supershifted by monospecific antibody to C/EBP␤ (38) . Others have further narrowed the C/EBP␤ binding site to Ϫ95 to Ϫ87 bp of the TNF␣ promoter (50) . The C/EBP␤ binds as a broad band because it is synthesized as a mixture of three translation products of 45, 38, and 20 kDa, all of which bind DNA (1, 41) . In contrast, c-Jun did not bind to this oligonucleotide (Fig. 6A, lanes 2 and 3) . Addition of increasing concentrations of c-Jun resulted in reduced binding of C/EBP␤ to the Ϫ100/Ϫ74 oligonucleotide (Fig. 6A, lanes 4 and  5) , similar to results reported for assay using a C/EBP␤-binding oligonucleotide from the IL-6 promoter (21). This inhibi- tion was often not as complete as is apparent in Fig. 6A , although inhibition was reproducible at higher concentrations of c-Jun.
Both c-Jun and C/EBP␤ bound to the Ϫ115/Ϫ74 oligonucleotide (Fig. 6A, lanes 6 to 8) . However, in contrast to the results observed with the shorter oligonucleotide lacking the c-Jun binding site, c-Jun did not inhibit C/EBP␤ binding to the Ϫ115/Ϫ74 oligonucleotide but resulted in the formation of a complex (Fig. 6A, lanes 9 and 10; Fig. 6B , lane 3 versus lanes 1 and 2) that contained both c-Jun and C/EBP␤. Monospecific antibodies to each transcription factor (Fig. 6B, lanes 4 and 6) , but not a control antibody (Fig. 6B, lane 5) , resulted in a supershift of a majority of the complex. As the ratio of C/EBP␤ to c-Jun was increased, greater residual C/EBP␤ binding was observed (data not shown). When limiting concentrations of c-Jun and or C/EBP␤ were used, no synergistic or cooperative binding to the Ϫ115/Ϫ74 TNF␣ promoter oligonucleotide was observed (data not shown).
Others have observed that C/EBP␤ may bind to AP-1 sites, thereby affecting gene expression (21, 23) . Therefore, we used the Ϫ115/Ϫ98 oligonucleotide to determine if C/EBP␤ was capable of binding to it or interfering with c-Jun binding. c-Jun but not C/EBP␤ bound to this site (Fig. 6C, lanes 2 and 1,  respectively) . Binding by c-Jun was inhibited by excess unlabeled Ϫ115/Ϫ98 oligonucleotide and a consensus AP-1-binding oligonucleotide but not an unrelated oligonucleotide (data FIG. 6 . The effect of C/EBP␤ and c-Jun interaction is DNA dependent. (A) Transcription factor c-Jun inhibits binding of C/EBP␤ to the Ϫ100/Ϫ74 but not the Ϫ115/Ϫ74 oligonucleotide. TNF␣ promoter oligonucleotides Ϫ100/Ϫ74 (lanes 1 to 5) and Ϫ115/Ϫ74 (lanes 6 to 10) were 32 P labeled and used as probes in the gel shift assay. c-Jun (1 and 3 g; lanes 2, 3, 7 , and 8) and C/EBP␤ (1.0 l of baculovirus nuclear extract; lanes 1 and 7), alone or combined (lanes 4, 5, 9, and 10), were loaded on a 4% polyacrylamide gel and run under nonreducing conditions. (B) c-Jun and C/EBP␤ form a complex binding to the Ϫ115/Ϫ74 TNF␣ promoter oligonucleotide. C/EBP␤ (1 l) and c-Jun (1 g) were added alone (lanes 1 and 2, respectively) or together (lanes 3 to 6) to the 32 P-labeled Ϫ115/Ϫ74 oligonucleotide. Antibody to C/EBP␤ (lane 4), control antibody (lane 5), or anti-c-Jun (lane 6) was added to the reaction mixture prior to loading on the gel. IgG, immunoglobulin G. (C) C/EBP␤ alters the mobility of c-Jun bound to the Ϫ115/Ϫ98 TNF␣ promoter oligonucleotide. C/EBP␤ (1 l) and c-Jun (1 g), alone (lanes 1 and 2) or together (lanes 3 to 5), were incubated with the 32 P-labeled Ϫ115/Ϫ98 oligonucleotide for 20 min at room temperature prior to running the gel. Antibodies to C/EBP␤ and c-Jun (lanes 4 and 5) were incubated with the transcription factors for 20 min at room temperature prior to adding the radiolabeled oligonucleotide. (D) The proximity of AP-1 and C/EBP␤ binding sites affects activation. A single copy of each of the AP-1 and C/EBP␤ binding sites from the TNF␣ promoter was inserted into pT81-Luc either unchanged (0 bp) or with 10 irrelevant oligonucleotides (10 bp) separating the two sites. The plasmids (5 g) were transfected by electroporation into wild-type U937 cells, keeping the total concentration of plasmid constant (16 g). After transfection the cells were treated with PMA and LPS as described in the text. Cells were harvested and analyzed as described in Materials and Methods. The parent plasmid was transfected in each experiment, and the results were subtracted prior to analysis. The results presented as the means Ϯ 1 SE are representative of four independent experiments. not shown), and the c-Jun-DNA complex reacted with antibodies specific for c-Jun (Fig. 6C, lane 5) . Although there was no specific binding of C/EBP␤ to this oligonucleotide (Fig. 6C,  lane 1) , addition of C/EBP␤ caused a portion of the c-Jun-DNA complex to migrate more rapidly (Fig. 6C, lane 3) , and this effect was reversed when antibodies specific for C/EBP␤ were added (Fig. 6C, lane 4) . This finding rules out the possibility that the changes in migration were due to nonspecific increases in protein concentration and suggests that C/EBP␤ and c-Jun interact in vitro, in a DNA binding-dependent fashion.
Next, the functional effect of the proximity of the AP-1 and C/EBP␤ binding sites of the TNF␣ promoter was examined. We constructed luciferase expression vectors that possessed a single copy of these two binding sites (Ϫ106 to Ϫ74 bp) from the TNF␣ promoter and one that possessed an irrelevant 10-bp segment between the two binding sites. When transfected into U937 cells differentiated with PMA and treated with LPS, a significant (P Ͻ 0.05) reduction of activation was observed when the 10 bp was inserted (Fig. 6D) . No change in DNA binding efficiency by C/EBP␤ and c-Jun was observed following the insertion of 10 bp between the C/EBP␤ and AP-1 binding sites in the Ϫ115/Ϫ74 oligonucleotide (data not shown). These observations support the importance of the proximity of these two binding sites in the synergistic activation of the TNF␣ promoter.
DISCUSSION
Our prior data indicated that C/EBP␤ was capable of binding to the Ϫ100/Ϫ74-bp region of the TNF␣ promoter and of activating the TNF␣ gene (38) . Expression of DN C/EBP␤ inhibited endogenous C/EBP␤ in myelomonocytic cells, suppressing the activation of the TNF␣ promoter (38) . Since C/EBP␤ is readily detected in the nuclei of monocytes not actively synthesizing TNF␣, activation of C/EBP␤ and/or interaction with an additional transcription factor may be necessary for expression of the TNF␣ gene. Our data demonstrate that c-Jun is capable of interacting with C/EBP␤ to activate the TNF␣ promoter in a unique manner that does not require the c-Jun transactivation domain.
Transient transfection of Jurkat T cells demonstrated that the macrophage-enriched nuclear transcription factor C/EBP␤ and the ubiquitous c-Jun interacted, resulting in synergistic activation of the TNF␣ promoter. These interactions involved the AP-1 and C/EBP␤ binding sites, located Ϫ106/Ϫ99 and Ϫ100/Ϫ74 bp, respectively, 5Ј from the transcription start site of the TNF␣ gene (Fig. 1) . The data indicate that the enhanced activation was independent of the c-Jun transactivation domain. Both wild-type and TAM-67 c-Jun were capable of amplifying the activation observed with C/EBP␤, indicating that the enhancement by c-Jun did not result from the additive or synergistic effects of heterologous transactivation domains.
Studies were performed with U937 cell lines that constitutively express endogenous C/EBP␤ to determine the potential relevance of the observations obtained with the Jurkat T cells. The overexpression of c-Jun and the expression of TAM-67 were both associated with enhanced secretion of TNF␣ in differentiated cells stimulated with LPS, suggesting the possibility that the enhanced expression of the TNF␣ gene in U937 cells was dependent on an interaction between c-Jun/TAM-67 and C/EBP␤. The results of the transient transfections in U937 cells expressing TAM-67 support a direct effect of TAM-67 and C/EBP␤ in the activation of the TNF␣ promoter in these cells. Alternatively, it is possible that c-Jun or TAM-67 affected differentiation or another mediator or transcription factor.
Since c-Jun and TAM-67 affect differentiation differently, an effect on this process seems an unlikely explanation (18, 45) . Although we cannot exclude the possibility that the effect on the TNF␣ gene was not secondary to that of another mediator or transcription factor, this is this first characterization, to our knowledge, in which the wild-type and transactivation domain mutant c-Jun interacted similarly in the activation of a gene.
In Jurkat T cells, the synergistic effect required that c-Jun and TAM-67 bind to the AP-1 site centered 102/103 bp upstream of the transcription start site. Truncations that abolished the AP-1 binding site or mutations of c-Jun that did not bind DNA did not manifest the synergistic effect. Similarly, truncation of this AP-1 site resulted in diminished activation of the TNF␣ promoter reporter in U937 cells expressing TAM-67. Our data indicate that the C/EBP␤ transactivation domain was required for the enhanced activation of the TNF␣ gene observed by the interaction between C/EBP␤ and c-Jun/TAM-67, since DN C/EBP␤ inhibited the activation of the TNF␣ promoter reporter in TAM-67-expressing U937 cells. These observations, together with the proximity of the two binding sites, suggest that physical interactions between C/EBP␤ and c-Jun/TAM-67, mediated by their leucine zippers (21) , may contribute to the enhanced TNF␣ activation.
The importance of the close proximity of these two binding sites is supported by the gel shift experiments. With the Ϫ115/ Ϫ74 oligonucleotide, both c-Jun and C/EBP␤ bound preferentially to the same oligonucleotide and were supershifted by monospecific antibody against either protein. Previous studies documented the inhibition of binding by C/EBP␤ to an IL-6 promoter oligonucleotide by c-Jun (21) . Although similar inhibition of binding was noted with the shorter Ϫ100/Ϫ74 TNF␣ oligonucleotide that did not bind c-Jun, suppression of binding of C/EBP␤ to the Ϫ115/Ϫ74 oligonucleotide, capable of binding both C/EBP␤ and c-Jun, was not observed. C/EBP␤ binds weakly to the TNF␣ promoter (38) . Binding of c-Jun/ TAM-67 at the neighboring cis site may facilitate the interaction of C/EBP␤ and c-Jun that is mediated through their leucine zipper domains (21) , stabilizing the C/EBP␤-DNA interaction and resulting in enhanced activation. Similar observations have been described for NF-B p65 interaction with c-Fos or c-Jun and C/EBP␤ interaction with NF-B, despite lack of enhanced or cooperative binding to DNA in gel shift experiments (37, 42) . Consistent with this possibility, insertion of 10 bp between the AP-1 and C/EBP␤ binding sites of the TNF␣ promoter resulted in diminished activation in PMA-LPS-treated U937 cells.
We did not find that interaction with NFAT, CBP, or p300 was responsible for the enhanced activation observed in this study. Consistent with the results observed with CBP and p300, E1A 12S demonstrated minimal or no effect on TNF␣ promoter activity in PMA-treated Jurkat T cells and in LPS stimulated THP-1 myelomonocytic cells (28) . If CBP or p300 were involved, inhibition by E1A might have been expected (4, 5, 28) . Consistent with our data concerning NFAT, cyclosporin A did not inhibit TNF␣ transcription in macrophages (34) . Additionally, in studies not presented, we have observed that c-Jun also interacted with NF-B proteins to enhance TNF␣ promoter activation. However, the transactivation domain of c-Jun was required, suggesting that the enhanced expression of TNF␣ observed in U937 cells in response to TAM-67 was not due to interactions with NF-B. Additionally, the NF-B binding site (Ϫ97 to Ϫ88 bp of the TNF␣ gene) is partially removed in the Ϫ95 TNF␣ promoter reporter construct, and NF-B fails to activate this promoter (data not shown).
The importance of the interactions between proteins binding to the Ϫ106/Ϫ99 and Ϫ97/Ϫ88 regions of the TNF␣ promoter has been identified by others (48) . ATF-2/Jun and NFATp, respectively, were identified as binding to these sites (48) . Independent and noncooperative binding at these two sites was responsible for optimal activation of the TNF␣ gene by anti-CD3 or ionomycin in Ar-5 T cells (48) . Our observations concerning the interaction between c-Jun and C/EBP␤ binding to these two regions were similar. We did not find evidence for cooperativity of binding of c-Jun and C/EBP␤ to the Ϫ115/Ϫ74 oligonucleotide or for the binding of heterodimers when the Ϫ115/Ϫ98 and the Ϫ100/Ϫ74 TNF␣ oligonucleotides were independently used.
Our data suggest that the suppression observed with c-Jun in our cotransfection assays using the Ϫ120 TNF␣ promoter reporter was due to squelching by the transactivation domain of c-Jun and not inhibition of binding to the promoter or the formation of heterodimers. The TAM-67 mutant, which lacks a transactivation domain, failed to suppress the C/EBP␤-induced activation of either the Ϫ120 or the Ϫ95 TNF␣ promoter reporter in PMA-activated Jurkat T cells. This result suggests that the inhibition of C/EBP␤ binding, as seen in the gel shift experiments using the Ϫ100/Ϫ74 oligonucleotide ( Fig.  6 ) and proposed as a mechanism of inhibition of activation of a C/EBP␤-driven promoter reporter (21), was not responsible for the inhibition of TNF␣ promoter activation observed with wild-type c-Jun in Jurkat T cells in assays employing the Ϫ120 TNF␣ promoter reporter. We cannot exclude the possibility that overexpression of c-Jun inhibited C/EBP␤ binding to the Ϫ95 TNF␣ promoter, since the effect of TAM-67 on C/EBP␤ binding to the Ϫ100/Ϫ74 oligonucleotide was not examined. Supporting the interpretation that interaction through the leucine zipper was not required for suppression, cotransfection of c-Jun-LZ also resulted in suppression of C/EBP␤-induced activation. The explanation for the lack of inhibition by the c-Jun-DBD is not clear, since wild-type c-Jun was suppressive of C/EBP␤-induced activation with the Ϫ95 TNF␣ promoterreporter, which lacked the AP-1 binding site centered at Ϫ102/ Ϫ103 bp. Our data do not support the consumption of CBP or p300 by c-Jun as a cause for the suppression, since their overexpression failed to reverse the inhibition. Suppression was not specific for c-Jun, however, since coexpression of c-Fos, which failed to enhance C/EBP␤-induced activation, also was suppressive. Since the CMV vector control did not suppress, inhibition was not due simply to promoter squelching. Suppression of TNF␣ secretion was not observed in the U937 cell lines stably transfected with wild-type c-Jun. It is possible that this phenomenon does not occur in these cells or that the concentration of c-Jun was not high enough to allow this effect to be observed.
Although PMA was not required to activate the TNF␣ promoter reporter constructs in U937 cells, the requirement for PMA in the Jurkat T cells deserves comment. PMA may be necessary to phosphorylate and activate C/EBP␤ (24, 30, 46, 47, 51, 52) . It is possible that the PMA induces an additional endogenous factor required for TNF␣ activation. We did not find evidence to suggest that NFAT, CBP, or p300 was involved. Binding to the Ϫ115/Ϫ74 TNF␣ oligonucleotide was observed constitutively with nuclear extracts from Jurkat cells not treated with PMA (data not presented). This binding was not due to C/EBP␤ and, although not further characterized, was greatly reduced following the addition of PMA, suggesting that PMA may inhibit a suppressive factor. For example, in pro-B-cell lines, CHOP was shown to bind C/EBP␤, inhibiting its ability to activate the Idl gene (40) . As an additional mechanism, PMA may also increase the concentration of C/EBP␤, which was under the control of a CMV promoter. PMA resulted in a two-to fivefold increase in the expression of a CMV-luciferase promoter reporter in Jurkat T cells (data not presented). Activation of the TNF␣ promoter was very sensitive to the concentration of C/EBP␤-expressing plasmid transfected, less than 5-fold at 1 g and Ͼ40-fold at 2 g. The ratio of the 20-kDa inhibitory and the 38-and 45-kDa stimulatory versions of C/EBP␤ are important in the overall ability of C/EBP␤ to become transcriptionally active within a cell. PMA may effect this ratio in favor of activation. This process is thought to be regulated at the level of mRNA translation. We have not been able to definitively ascribe the effects of PMA to any one of these mechanisms.
AP-1 and C/EBP␤ are also known to cooperate in the regulation of other genes, including the chicken myelomonocytic growth factor (cGMF) gene and the human TSF-6 and collagenase-1 genes (11, 23, 32 ). An AP-1 binding site in the proximal promoter and a C/EBP␤ site approximately 2,000 bp upstream appeared to regulate the human collagenase-1 gene independent of one another (11) . For the cGMF and the TSF-6 genes, mutation of the AP-1 binding sites in the promoter reporters reduced, and mutation of the C/EBP␤ sites essentially abolished, activation of the genes. Similarly, deletion of the AP-1 site centered at Ϫ102/Ϫ103 bp of the TNF␣ promoter abolished the synergistic effect of the coexpression of c-Jun on C/EBP␤-induced activation. Although we have not developed point mutations in the TNF␣ promoter reporter constructs to precisely define the location important for C/EBP␤-induced activation, we previously demonstrated that the Ϫ36 TNF␣ promoter reporter, lacking the C/EBP␤ binding site, was not active in myelomonocytic U937 cells which constitutively express high concentrations of C/EBP␤ or in Jurkat T cells transfected with C/EBP␤ (38) . Further studies will be required to determine the importance of the interaction between c-Jun and C/EBP␤ in the activation of the cellular TNF␣ gene in monocytes/macrophages and other cell types expressing C/EBP␤.
